ArticleTranslational andrology and urology2025
Predicting bone metastasis and high-grade Gleason scores in prostate cancer: a retrospective study integrating clinical features and magnetic resonance imaging radiomics.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical applications of MRI-based artificial intelligence in spinal metastases: A systematic review.Journal of bone oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is a common malignant tumor in older men, and bone metastasis is its most frequent form. Once bone metastasis occurs, survival drops sharply. The Gleason score is the standard tool for judging how aggressive the cancer is; men with high-risk disease face higher chances of treatment failure and death. Therefore, early detection and prediction of bone metastasis and high Gleason scores by magnetic resonance imaging (MRI) are clinically important. In this study, we analyzed clinical and MRI data from 168 PCa patients to evaluate the role of clinical features and MRI-based radiomics in predicting bone metastasis and high-grade Gleason scores. Methods: This retrospective study included 168 patients with pathologically confirmed PCa from Zhongshan Hospital of Traditional Chinese Medicine. Clinical and pathological data, as well as MRI images, were collected. Radiomics and clinical features were extracted and divided into training and testing sets using a random ratio. Feature selection was performed using Results: Patients with bone metastasis and high-grade Gleason Scores had significantly higher levels of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) compared to those without bone metastasis and with low-grade Gleason scores (P<0.05). In the testing set, the best-performing model for predicting bone metastasis was the Extreme Gradient Boosting (XGBoost) model that used clinical features combined with radiomics features, with an AUC of 0.875, which was superior to the AUC of 0.732 for radiomics features alone. For predicting high-grade Gleason scores, the XGBoost model using clinical features combined with radiomics features also performed best, with an AUC of 0.830, outperforming the AUC of 0.778 for radiomics features alone. The most significant clinical feature identified was fPSA, while the most significant radiomics features were log-sigma-5-0-mm-3D_glszm_ZoneEntropy for bone metastasis and wavelet-HLH_gldm_HighGrayLevelEmphasis for high-grade Gleason scores respectively. Conclusions: We proposed a predictive model that integrated clinical features and radiomics features obtained from prostate MRI, offering a non-invasive and radiation-free approach to predict bone metastasis and high-grade Gleason scores in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.